

**ANNUAL REPORT**  
**OF**  
**MEDICAMEN ORGANICS LIMITED**  
**(FINANCIAL YEAR-2022-23)**

<b>Sr No.</b>	<b>Nature of Documents</b>
<u>1.</u>	Independent Auditor Report
<u>2.</u>	Balance Sheet
<u>3.</u>	Notice
<u>4.</u>	Director report
<u>5.</u>	List of Shareholders



# MEDICAMEN Organics Limited

Regd. & Corporate Office : 10, Community Centre No. 2, Ashok Vihar, Phase-II, Delhi-110052 (India)

Tel.: 011-27430249 | Tel-Fax : 011-27138171

Sales Office : 104, Sawan Park Extn., Ashok Vihar, Phase-III, Delhi-110052 (India)

E-mail : chairmen@mediorganics.in | CIN No. : U74899DL1995PLC066416 | GSTIN : 07AABCM4302P1ZF

## LIST OF SHAREHOLDERS

As on 31<sup>st</sup> March 2023

S. NO.	NAME OF THE SHAREHOLDER	NUMBER OF SHARES	% OF SHAREHOLDING
1.	MR. BAL KISHAN GUPTA	4,486,650	74.78%
2.	MR. ASHUTOSH GUPTA	619,500	10.33%
3.	SHIVANI CHOPRA	6,00,000	10%
4.	SUCHITA GUPTA	300	0.005%
5.	RITU GUPTA	2,86,500	4.78%
6.	B. K GUPTA & SONS HUF	300	0.005%
7.	ISHAN GUPTA C/O MRS. SUCHITA GUPTA	6750	0.112%
	<b>Total</b>	<b>60,00,000</b>	<b>100</b>

For and on behalf of the board of directors  
MEDICAMEN ORGANICS LIMITED

Bal Kishan  
Gupta

Digitally signed by  
Bal Kishan Gupta  
Date: 2023.11.28  
16:44:37 +05'30'

BAL KISHAN GUPTA  
Director  
DIN: 00032772

Ashutos  
h Gupta

Digitally signed  
by Ashutosh  
Gupta  
Date: 2023.11.28  
16:43:52 +05'30'

ASHUTOSH GUPTA  
Director  
DIN: 00039995

Place: New Delhi  
Date: 28-11-2023

## Works :

Unit 1 : Plot No. 60, Sector-6A, I.I.E. SIDCUL, Haridwar - 249 403 (U.K.) | GSTIN : 05AABCM4032P1ZJ

Unit 2 : Plot No. 61, Sector-6A, I.I.E. SIDCUL, Haridwar - 249 403 (U.K.) | GSTIN : 05AABCM4032P3ZH

# ASHOK SHARMA & ASSOCIATES

## CHARTERED ACCOUNTANTS

311, "DEEPSHIKHA",  
8, RAJENDRA PLACE,  
NEW DELHI - 110 008  
PHONE - 2576 9764

### INDEPENDENT AUDITOR'S REPORT

#### **The Members of MEDICAMEN ORGANICS LIMITED** **Report on the Financial Statements**

We have audited the accompanying Financial Statements of **MEDICAMEN ORGANICS LIMITED** ("the Company") which comprise the Balance Sheet as at March 31, 2023, the Statement of Profit and Loss and the statement of Cash Flows Statement for the year ended on that date, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2006, as amended ("AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, the Profit & Loss and its Cash Flows for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Financial Statements.

#### **Key audit matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and informing our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

#### **Information Other than the Financial Statements and Auditor's Report Thereon**

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report and Annual Return, but does not include the Financial Statements and our auditors' report thereon.

Our opinion on the Financial Statements does not cover the Board Report and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

Contd. .... 2...



If, based on the work we have performed, we conclude that there is a material misstatement in this other information; we are required to report that fact. In absence of any material or information in this regard, we have nothing to report on the same.

### **Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

### **Auditors' Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.

Contd. ....3...



However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### Report on Other Legal and Regulatory Requirements

1. As required by section 143 (3) of the Act, based on our audit we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
  - b. In our opinion proper books of account as required by law relating to preparation of the Financial Statements have been kept by the Company so far as it appears from our examination of those books;
  - c. The Balance Sheet, the Statement of Profit and Loss and the Statement of Cash Flow Statement dealt with by this Report are in agreement with the books of account for the purpose of preparation of these Financial Statements.
  - d. In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - e. On the basis of written representations received from the directors as on March 31, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
  - f. With respect to the adequacy of the internal financial controls with reference to Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to Financial Statements.
  - g. With respect to the other matter to be included in the Auditor's Report in accordance with Rule-11 of the Companies (Audit and Auditors) Rule, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
    - i) The Company does not have any pending litigations.
    - ii) The Company did not have any long-term contracts including derivatives contracts.
    - iii) There were no amounts which required to be transferred by the Company to the Investor Education and Protection Fund.

Contd. ....4...



2. As required by the Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143(11) of the Act, we give in 'Annexure B' a statement on the matters specified in paragraphs 3 and 4 of the Order.
3. The company has not maintained Audit Trail in its books of accounts since, as per the proviso to rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable for the company w.e.f. April 1, 2023, reporting under this clause is not applicable to it.

For ASHOK SHARMA & ASSOCIATES  
CHARTERED ACCOUNTANTS

(ADITYA CHOUDHARY)  
PARTNER

MEMBERSHIP NO.: 528486

PLACE : NEW DELHI

DATE : 07/09/2023

UDIN- 23528486BGXCRN3705

**MEDICAMEN ORGANICS LIMITED**

Financial Year – 2022-2023

**ANNEXURE 'A' TO THE INDEPENDENT AUDITORS' REPORT**

**[Referred to in paragraph 1 under the heading of "Report on other legal and Regulatory Requirement" of our report of even date]**

(i) In respect of Fixed Asset of the company:

- (a) (A) According to the information and explanations given to us and on the basis of the books and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that the company has maintained proper records showing full particulars including quantitative details and situation of its Property, Plant & Equipment.
- (B) According to the information and explanations given to us and on the basis of the books and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that the company has maintained proper records showing full particulars of Intangible assets.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all Property, Plant and Equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain Property, Plant and Equipment were verified during the year. In our opinion, the periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examinations of the records of the Company, the title deeds of immovable properties as accounted for in the books of Account are held in the name of the company.
- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right-to-use assets) or Intangible assets or both during the year.
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made there under.

Contd. ....1...



- (ii) (a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were 10% or more in the aggregate for each class of inventory.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. In our opinion, there is no material difference in the quarterly statement of current assets filed by the company with bankers with regard to working capital limits.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made investments in companies, firms Limited Liability Partnerships or any other parties during the year. The company has provided guarantee or security and granted loans, unsecured, to companies, Joint ventures and other parties during the year.
- (a) The Company has not provided loans and stood guarantee during the year.
- (b) According to the information and explanations given to us and based on the audit procedures conducted by us, we are of the opinion that the clause is not applicable to the company.
- (c) According to the information and explanations given to us, the clause is not applicable to the company.
- (d) According to the information and explanations given to us the clause is not applicable to the company.
- (e) According to the information and explanations given to us the clause is not applicable to the company.
- (f) According to the information and explanations given to us the clause is not applicable to the company.
- (iv) The Company has not granted any Loans or Advances or given any security or made any Investment as per the provisions of Section 185 and 186 of the Companies Act, 2013 .



(v) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) According to the information and explanations given to us, the Central Government has not prescribed the maintenance of cost records under Section 148 (1) of the Companies Act, 2013 for the services provided by it. Accordingly, clause 3 (vi) of the Order is not applicable.

(vii) In respect of statutory dues:

(a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Goods and Services Tax ('GST'), Provident fund, Employees' State Insurance, Income-Tax, Duty of Customs, Cess and other material statutory dues have generally been regularly deposited with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of GST, Provident fund, Employees' State Insurance, Income-tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2023 for a period of more than six months from the date they became payable.

(c) According to the information and explanations given to us, there are no dues of GST, Provident fund, Employees' State Insurance, Income-tax, Sales tax, Service tax, Duty of Customs, Value added tax, Cess or other statutory dues which have not been deposited by the Company on account of disputes, except for the following:

Name of the Statute	Nature of the Dues	Amount (Rs. In Lakhs)	Period	Forum where dispute is pending
Income Tax Department	Income Tax	13.27	Assessment year- 2017-2018	Commissioner of Income Tax

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-Tax Act, 1961 as income during the year.



- (ix) (a) According to the information and explanations given to us and on the basis of our audit procedures, company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our audit procedures, the Company has not been declared wilful defaulter by any bank or financial institution or other lender.
- (c) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the financial statements of the Company, term loans were applied for the purpose for which the loans were obtained.
- (d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that funds have been raised on short-term basis by the Company have not been utilized for long term purposes.
- (e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Companies Act, 2013, since the company does not have any subsidiary accordingly, clause 3(ix)(e) of the Order is not applicable.
- (f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries as defined under the Companies Act, 2013. accordingly, clause 3(ix)(f) of the Order is not applicable the company does not have any subsidiary.
- (x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.
- (xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.
- (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

Contd. ....5...



- (c) According to the information and explanations given to us, no whistle blower complaints received by the Company during the year.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Sections 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the standalone financial statements as required by the applicable Accounting Standards.
- (xiv) (a) According to the information and explanations given to us, In our opinion the Company has an adequate Internal audit system commensurate with the size and the nature of its business.
- (b) We have not been provided any internal audit reports for the year under audit, which as explained is not issued since there is no system for the same, in determining the nature, timing and extent of our audit procedures.
- (xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a), 3(xvi)(b) of the Order are not applicable.
- (b) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (c) According to the information and explanations provided to us during the course of audit, the Group does not have any CIC. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.
- (xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- (xviii) There has been no resignation of the Statutory Auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

Contd. ....6...



- (xix) According to the information and explanations given to us, and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of

meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- (xx) (a) In our opinion and according to the information and explanations given to us the provisions of section 135 of the said Act are not applicable to the company.
- (b) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Companies Act, 2013 pursuant to any ongoing project. Accordingly, clause 3(xx)(b) of the Order are not applicable.

PLACE : NEW DELHI  
DATE : 07/09/2023

UDIN - 23528486BGXCRN3705

For ASHOK SHARMA & ASSOCIATES  
CHARTERED ACCOUNTANTS

(ADITYA CHOUDHARY)

PARTNER

MEMBERSHIP NO.: 528486

**MEDICAMEN ORGANICS LIMITED**  
Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II New Delhi - 110052  
CIN : U74899DL1995PLC066416  
**BALANCE SHEET AS AT 31.03.2023**

		(Rs. in Lakhs)	
PARTICULARS	Note No.	Figures as at the end of	
		current reporting period ( as at 31.03.2023)	previous reporting period ( as at 31.03.2022)
<b>I. EQUITY AND LIABILITIES</b>			
1 Shareholders' funds			
(a) Share Capital	2	600.00	600.00
(b) Reserves and Surplus	3	269.13	146.93
		<b>869.13</b>	<b>746.93</b>
2 Share Application Money Pending Allotement		-	-
3 Non- current liabilities			
(a) Long-term borrowings	4	55.40	98.06
(b) Deferred Tax liabilities (Net)	5	33.48	31.39
(c) Long-term Provisions	6	21.61	22.98
		<b>110.49</b>	<b>152.44</b>
4 Current Liabilities			
(a) Short term borrowings	7	1124.09	926.52
(b) Trade payables		-	-
(i) Outstanding dues of Micro and Small Enterprises		-	-
(ii) Outstanding dues of Creditors other than Micro and Small Enterprises	8	898.78	768.03
(c) Other current liabilities	9	60.87	13.89
(d) Short term provisions	10	4.99	4.57
		<b>2088.74</b>	<b>1713.01</b>
<b>TOTAL</b>		<b>3068.36</b>	<b>2612.38</b>
<b>II ASSETS</b>			
1. Non-current assets			
(a) Property, Plant & Equipment	11		
(i) Tangible assets		980.77	1031.66
(ii) Intangible assets		0.87	1.06
(iii) Capital work-in-progress	12	0.00	0.00
(b) Deferred Tax Assets (Net)	13	0.00	0.00
(c) Long-term loans and advances	14	24.82	23.76
		<b>1006.46</b>	<b>1056.48</b>
2. Current assets			
(a) Inventories	15	613.90	472.18
(b) Trade receivables	16	1033.14	624.54
(c) Cash and cash equivalents	17	55.91	44.50
(d) Short-term loans and advances	18	358.26	413.98
(e) Other current assets	19	0.69	0.69
		<b>2061.90</b>	<b>1555.90</b>
<b>TOTAL</b>		<b>3068.36</b>	<b>2612.38</b>
See accompanying notes to the financial statements	1-35		

As per our attached Report of Even Date

For Ashok Sharma & Associates  
Chartered Accountants

Aditya Choudhary  
(Partner)  
Membership No.: 528486  
UDIN :  
Place : New Delhi  
Date: 07-09-2023

UDIN-23528486 BQXCRN3705

For & on behalf of the Board of Directors  
For MEDICAMEN ORGANICS LTD.

Director

B.K. Gupta  
(Director)  
DIN:00032772

Director

Ashutosh Gupta  
(Director)  
DIN:00039995

**MEDICAMEN ORGANICS LIMITED**

Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II New Delhi - 110052

CIN : U74899DL1995PLC066416

**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31.03.2023**

	PARTICULARS	Note No.	(Rs. In Lakhs)	
			Figures as at the end of	
			current reporting period ( as at 31.03.2023)	previous reporting period ( as at 31.03.2022)
I	Revenue from operations:			
	Sale of Products		2092.71	2057.02
	Sale of Services		122.00	40.50
II	Other income	20	2214.71	2097.52
			80.74	20.52
III	Total Revenue (I + II)		2295.45	2118.04
IV	Expenses			
	Cost of Materials Consumed	21	1397.65	1411.92
	Purchase of Traded Goods		-	-
	Changes in inventories of finished goods, work in progress and Stock-in- trade	22	-59.29	-71.36
	Employee benefits expense	23	315.66	287.36
	Finance Costs	24	55.54	42.85
	Depreciation and amortization expense	11	80.01	80.73
	Other expense	25	377.54	353.64
	Total Expense		2167.11	2105.14
V	Profit before exceptional and extraordinary items and tax (III-IV)		128.35	12.90
VI	Exceptional Items		-	-
VII	Profit before extraordinary items and tax (V-VI)		128.35	12.90
VIII	Extraordinary items(Loss of Delhi allocated to both unts in the ratio of Turnover		-	-
IX	Profit before tax (VII-VIII)		128.35	12.90
X	Tax expense:			
	(1) Current tax		1.00	1.00
	(2) Deferred tax		2.09	4.07
XI	Profit/(Loss) for the period from continuing operations (IX - X)		125.26	7.83
XII	Profit/(Loss) for the period		125.26	7.83
XIII	Brought Forward Profit/(Loss) from Previous Year		55.49	44.58
XIV	Net Profit/(Loss) carried over to Balance Sheet		180.75	55.49
XV	Earnings per equity share:			
	(1) Basic		2.09	0.13
	(2) Diluted		2.09	0.13
	See accompanying notes to the financial statements	1-35		

As per our attached Report of Even Date

For Ashok Sharma & Associates

Chartered Accountants

**Aditya Choudhary**

Partner

Membership No.: 528486

UDIN :

Place : New Delhi

Date: 07-09-2023

U DIN-23528486 BQXC RN3705

For & on behalf of the Board of Directors

FOR MEDICAMEN ORGANICS LTD.

**B.K. Gupta**

Director

DIN:00032772

**Ashutosh Gupta**

Director

DIN:00039995

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH 2023**

Particulars	(Rs. in Lakhs)	
	Figures as at the end of	
	current reporting period ( as at 31.03.2023)	previous reporting period ( as at 31.03.2022)
<b>Cash flow from operating activities</b>		
Net Profit/(Loss) after tax from continuing operations	125.26	7.83
<b>Non-cash adjustment to reconcile profit before tax to net cash flows</b>		
Provision for Taxation	-	-
Depreciation/amortization on continuing operation	80.01	80.73
Interest expense	55.54	42.85
Interest income	-0.98	-2.17
Adjustment for Deferred Tax	2.09	4.07
<b>Operating profit before working capital changes</b>	<b>261.92</b>	<b>133.31</b>
Movements in working capital :		
Increase/(decrease) in trade payables	130.75	11.90
Increase / (decrease) in long-term provisions	-1.38	3.34
Increase / (decrease) in short-term provisions	0.42	-9.39
Increase/(decrease) in other current liabilities	46.98	-26.42
Decrease/(increase) in trade receivables	-408.59	128.37
Decrease/(increase) in inventories	-141.71	-206.10
Decrease / (increase) in long-term loans and advances	-1.06	-9.62
Decrease / (increase) in short-term loans and advances	55.71	-44.33
Decrease/(increase) in other current assets	-	6.94
Direct taxes paid (net of refunds)	-3.59	2.52
<b>Net cash flow from/ (used in) operating activities (A)</b>	<b>-60.56</b>	<b>-9.49</b>
<b>Cash flows from investing activities</b>		
Purchase of fixed assets, including intangible assets and CWIP	-28.93	-61.64
Interest received	0.98	2.17
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>-27.95</b>	<b>-59.47</b>
<b>Cash flows from financing activities</b>		
Proceeds from issuance of share capital	-	-
Share Application Money	-	-
Repayment of long-term borrowings	-42.12	-16.85
Proceeds from short-term borrowings	197.57	83.01
Interest paid	-55.54	-42.85
<b>Net cash flow from/(used in) in financing activities (C)</b>	<b>99.91</b>	<b>23.31</b>
Net increase/(decrease) in cash and cash equivalents (A + B + C)	<b>11.41</b>	<b>-45.64</b>
Cash and cash equivalents at the beginning of the year (D)	44.50	90.15
<b>Cash and cash equivalents at the end of the year ( E)</b>	<b>55.91</b>	<b>44.50</b>
<b>Difference in above D and E</b>	<b>11.41</b>	<b>-45.64</b>

See accompanying notes to the financial statements

1-35

As per our attached Report of Even Date

For Ashok Sharma & Associates

Chartered Accountants

Aditya Choudhary

Partner

Membership No.: 528486

UDIN :

Place : New Delhi

Date: 07-09-2023

UDIN - 23528486 B9XC RN3705

For MEDICAMEN ORGANICS LTD.  
For & on behalf of the Board of Directors



B.N. Gupta  
Director  
DIN:00032772



Ashutosh Gupta  
Director  
DIN:00039995

**MEDICAMEN ORGANICS LIMITED**  
10, Community Centre No.2, Ashok Vihar, Phase-II, Delhi-110 052

**SCHEDULE FORMING PART OF THE BALANCE SHEET**

**Notes forming Part of Accounts**

**NOTE '1':**

**(i) SIGNIFICANT ACCOUNTING POLICIES**

**General:** The Accounts are prepared on the historical cost basis and on the accounting principle of going concern. All expenses and incomes to the extent considered payable and receivable respectively unless stated otherwise, have been accounted for on mercantile basis. Accounting Policies not specifically referred to otherwise are consistent and in accordance with generally accepted accounting principles.

**Fixed assets:** The gross block of fixed assets is stated at historical cost which includes duties and taxes.

**Depreciation:** Depreciation is provided on straight line method at the rates and manners specified in schedule II of the Companies Act, 2013 on fixed assets used for the purpose of business.

**Foreign Exchange Transactions:** Transactions in foreign currencies are recorded at the rate of exchange in force at the date of transaction. Receivables and Liabilities (considered good), in foreign currency at the year end, are converted at the rate of exchange prevailing at the end of financial year. Export sales are accounted for at the time of dispatch of the material from the factory for export.

**Export Benefits:** Export benefits are provided on accrual basis on satisfaction of condition relevant to the same.

**(ii)** The closing stock as on 31<sup>st</sup> March, 2023 is as taken, valued and certified by the management.

- Raw Material, Packing Material and Finished Goods are valued at cost or net realisable value whichever is lower.
- Work in Progress are valued at estimated cost
- Stores and Spares are valued at cost.

**(iii)** The Company has provided Employees Benefits as per the Accounting Standard-15 issued by the Institute of Chartered Accountants of India. Provision for Gratuity and Leave Encashment have been made in the books of accounts on the basis of actuarial valuation using the Project Unit Credit Method.

**(iv)** Company has made provision for deferred tax effect on the difference of depreciation between the amount, as per Income tax rules and profit & loss account for the year and accumulated retirement benefit provided for during the year.



For MEDICAMEN ORGANICS LTD  
  
Director

## NOTES FORMING PART OF ACCOUNTS

(Rs. in Lakhs)

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

## NOTE '2'

## SHARE CAPITAL

## -Authorised

60,00,000 Equity Shares of Rs.10/- each

[Previous Year : 60,00,000 Equity Shares of Rs.10/- each]

600.00

600.00

## -Issued, Subscribed and Paid up

60,00,000 Equity Shares of Rs.10/- each fully paid-up.

[Previous Year : 60,00,000 Equity Shares of Rs.10/- each]

600.00

600.00

## TOTAL

600.00

600.00

	Nos	Amt(Rs)	Nos	(Rs. in Lakhs) Amt(Rs)
- Reconciliation of Shares:				
Opening Share Capital	60.00	600.00	60.00	600.00
Add: Shares issued During the year	-	-	-	-
Add: Bonus Shares Issued	-	-	-	-
Total	60.00	600.00	60.00	600.00
Less: Buy back of Shares	-	-	-	-
Less Reduction in Capital	-	-	-	-
Closing Share Capital	60.00	600.00	60.00	600.00

## -List of Share holders having 5% or more Shares (In Nos)

Name Of Shareholders	In Nos	In %	In Nos	In %
1. Bal Kishan Gupta	44.87	75	44.87	75
2. Ashutosh Gupta	6.20	10	6.20	10
3. Shivani Chopra	6.00	10	6.00	10

## -Shares Held By Promoters (In Nos)

Name Of Promoters	Figures as at the end of current reporting period ( as at 31.03.2023)		
	No of Shares	% of Total Shares	% Changes During The Year
1. Bal Kishan Gupta	44,86,650	74.78	No change
2. Ashutosh Gupta	6,19,500	10.33	No change

Name Of Promoters	Figures as at the end of Previous reporting period ( as at 31.03.2022)		
	No of Shares	% of Total Shares	% Changes During The Year
1. Bal Kishan Gupta	44,86,650	74.78	No change
2. Ashutosh Gupta	6,19,500	10.33	No change

For MEDICAMEN ORGANICS LTD.

  
 Director

  
 Director

(Rs. in Lakhs)

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

## NOTE '3'

## RESERVES AND SURPLUS

## Capital Reserve

## Securities Premium

## Profit and Loss Account

Opening Balance	55.49	44.60
Add: Adjustment of Provision of Taxation	-3.05	3.05
Add: Profit/(Loss) During The Year	125.26	7.83
Balance	177.69	55.49
Less: Bonus Shares Issued	-	-
Less: Fixed Assets Written Off	-	-
Closing Balance	177.69	55.49
<b>TOTAL</b>	<b>269.13</b>	<b>146.93</b>

(Rs. in Lakhs)

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

## NOTE '4'

## LONG TERM BORROWINGS

## -Secured

## Term Loans

## -From Bank

Term Loan from Axis Bank Ltd	29.88	63.84
------------------------------	-------	-------

## Secured by way of :

- i) First Charge on entire Fixed Assets and Current Assets of the Company both present and future including Land & Building situated at Plot No.60 & 61, Sector-6A, Sidcul, Hardwar
- ii) Personal Guarantee of two Directors

Term Loan from Axis Bank Ltd. (Vehicle Loan)	14.69	20.26
--	-------	-------

[Secured by way of Hypothecation of vehicles]

[ Repayable in 60 Instalments for Kia-Carnival Vehicle started from 10.08.2021 and last instalment due on 10.07.2026 EMI of Rs.53973/-]

## Term Loan from Axis Bank Ltd. (Vehicle Loan)

and [ Repayable in 60 Instalments for Creta Vehicle started from 10.04.2022 and last instalment due on 10.03.2027 EMI of Rs.33763/-]	10.83	13.97
--	-------	-------

## TOTAL

55.40

98.06



For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

(Rs. in Lakhs)

**NOTE '5'**

**DEFERRED TAX LIABILITY**

Deferred Tax Liabilities (Net)	33.48	31.39
<b>TOTAL</b>	<b>33.48</b>	<b>31.39</b>

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

**NOTE '6'**

(Rs. in Lakhs)

**LONG TERM PROVISIONS**

Provision For Employee Benefits

- Gratuity	17.23	18.91
- Leave Encashment	4.38	4.08

<b>TOTAL</b>	<b>21.61</b>	<b>22.98</b>
--------------	--------------	--------------

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

**NOTE '7'**

(Rs. in Lakhs)

**SHORT TERM BORROWINGS**

Loans repayable on demand

-Secured

Working Capital Loan from Axis Bank Ltd	522.48	443.29
---	--------	--------

Secured by way of :

- First Charge on entire Fixed Assets and Current Assets of the Company both present and future including Land & Building situated at Plot No.60 & 61 Sector-6A, Siraul Hardwar
- Personal Guarantee of two Directors

Current maturities of long term borrowings	8.71	8.15
--	------	------

-Unsecured

Unsecured Loans

From Related parties	592.91	475.07
----------------------	--------	--------

<b>TOTAL</b>	<b>1124.09</b>	<b>926.52</b>
--------------	----------------	---------------



For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

Particulars	Figures For the Current Reporting Period (as at 31.03.2023)				
	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
<b>NOTE '8'</b>					
<b>TRADE PAYABLES</b>					(Rs. in Lakhs)

MSME	-	-	-	-	-
Others	834.51	47.92	16.35	0.00	898.78
Dispute dues-MSME	-	-	-	-	-
Dispute dues Others	-	-	-	-	-
<b>Total</b>					<b>898.78</b>

Particulars	Figures For the Previous Reporting Period (as at 31.03.2022)				
	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
<b>NOTE '8'</b>					
<b>TRADE PAYABLES</b>					(Rs. in Lakhs)
MSME	-	-	-	-	-
Others	723.17	36.94	7.92	0.00	768.03
Dispute dues-MSME	-	-	-	-	-
Dispute dues-Others	-	-	-	-	-
<b>Total</b>					<b>768.03</b>

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
<b>NOTE '9'</b>		
<b>OTHER CURRENT LIABILITIES</b>		(Rs. in Lakhs)
Creditors for Capital Goods/Expenses	-	-
Statutory Dues	14.11	5.57
Deposits- Security Deposits	-	-
Interest Accrued and Due on Borrowings	-	-
Interest Accrued but not Due on Borrowings	-	-
Income received in Advance	-	-
Any Other Current Liability	46.76	8.32
<b>TOTAL</b>	<b>60.87</b>	<b>13.89</b>

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
<b>NOTE '10'</b>		
<b>SHORT TERM PROVISIONS</b>		(Rs. in Lakhs)

Provision for Employee Benefits		
- Leave Encashment	0.33	0.35
- Gratuity	0.37	0.39
- Bonus	0.99	2.83
Other Provisions:		
- Provision for Taxation	3.30	1.00
<b>TOTAL</b>	<b>4.99</b>	<b>4.57</b>

For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

Note:11 Schedule of Tangible Assets  
As on 31.03.2023

(Rs. in Lakhs)

	GROSS BLOCK				DEPRECIATION BLOCK				NET BLOCK		
Description	Gross Value as on 01/04/2022	Addition during the Year	Disposal during the Year	Gross Value as on 31/03/2023	Depreciation as on 01/04/2022	Fixed Asset Written of	Depreciation during the Year	Adjustment during the period	Total as on 31/03/2023	W.D.V. as on 31/03/2023	W.D.V. as on 31/03/2022
Land-Hardwar	53.71	-	-	53.71	7.61	-	0.60	-	8.21	45.50	46.09
Building	478.36	1.26	-	479.62	115.09	-	15.15	-	130.24	349.37	363.26
Plant & Machinery	568.49	14.10	-	582.59	207.84	-	27.27	-	235.11	347.48	360.65
Machinery	2.52	-	-	2.52	2.05	-	0.12	-	2.17	0.35	0.47
Electrical Install	71.22	4.02	-	75.24	50.55	-	3.38	-	53.93	21.31	20.66
A.C Plant	153.28	-	-	153.28	86.07	-	9.16	-	95.23	58.04	67.21
Office Equipment	5.47	0.52	-	5.99	4.20	-	0.36	-	4.56	1.43	1.27
Computer	13.88	0.40	-	14.28	11.80	-	0.88	-	12.68	1.60	2.07
Furniture & Fix.	29.36	-	-	29.36	11.24	-	2.73	-	13.97	15.39	18.12
Generator Set	20.63	5.90	-	26.53	12.03	-	1.52	-	13.55	12.97	8.60
Lab Equipments	84.00	0.95	-	84.95	33.18	-	6.72	-	39.90	45.05	50.83
Lift	27.61	-	-	27.61	9.88	-	1.67	-	11.55	16.06	17.73
Misc Fixed Assets	0.34	-	-	0.34	0.24	-	0.02	-	0.26	0.09	0.10
Other Machines	0.22	-	-	0.22	0.15	-	0.01	-	0.16	0.05	0.06
Water Pump	35.57	-	-	35.57	10.02	-	2.33	-	12.35	23.22	25.55
Car	91.97	1.79	-	93.76	43.82	-	7.73	-	51.55	42.21	48.15
Cycle	0.02	-	-	0.02	0.02	-	0.00	-	0.02	0.00	0.00
Mobile Phone	0.88	-	-	0.88	0.04	-	0.17	-	0.21	0.67	0.84
Total	1637.51	28.93	-	1666.44	605.85	-	79.82	-	685.67	980.77	1031.66
Prev. Year	1575.87	61.64	-	1637.51	525.32	-	80.53	-	605.85	1031.66	1050.56

Note:11 Schedule of Intangible Assets

As on 31.03.2023

(Rs. in Lakhs)

	GROSS BLOCK			DEPRECIATION BLOCK					NET BLOCK		
Description	Gross Value as on 01/04/2022	Addition during the Year	Disposal during the Year	Gross Value as on 31/03/2023	Depreciation as on 01/04/2022	Fixed Asset Written of	Depreciation during the Year	Adjustment during the period	Total as on 31/03/2023	W.D.V. as on 31/03/2023	W.D.V. as on 31/03/2022
Patent/Trademark	8.01	-	-	8.01	6.94	-	0.20	-	7.14	0.87	1.06
Total	8.01	-	-	8.01	6.94	-	0.20	-	7.14	0.87	1.06
Prev. Year	8.01	-	-	8.01	6.75	-	0.20	-	6.94	1.06	1.26

For MEDICAMEN ORGANICS LTD.

*Singh*  
Director

*Debut Singh*  
Director

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

(Rs. in Lakhs)

**NOTE '12'**

**CAPITAL WORK IN PROGRESS (Pending Capitalisation)**

Advances To Suppliers

Less: transferred to Fixed Assets

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

(Rs. in Lakhs)

**NOTE '13'**

**DEFERRED TAX ASSETS**

Deferred Tax Assets (Net)

**TOTAL**

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

(Rs. in Lakhs)

**NOTE '14'**

**LONG TERM LOANS AND ADVANCES**

*Secured Considered Good:*

Capital Advances

Security Deposits

Loans and Advances to Related Parties

Other Loans and Advances (Specify Nature)

*Unsecured Considered Good:*

Security Deposits

*Doubtful:*

Capital Advances

Security Deposits

Loans and Advances to Related Parties

Other Loans and Advances (Specify Nature)

**TOTAL**

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

(Rs. in Lakhs)

**NOTE '15'**

**INVENTORIES**

Raw Material

Packing Material

Work In Process

Finished Goods

Stock-in-Trade

Stores and Spares

Goods in Transit

**TOTAL**

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
Raw Material	227.29	183.07
Packing Material	224.50	186.30
Work In Process	150.59	66.10
Finished Goods	11.52	36.21
Stock-in-Trade	-	-
Stores and Spares	-	0.50
Goods in Transit	-	-
<b>TOTAL</b>	<b>613.90</b>	<b>472.18</b>



For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

Particulars	Figures For the Current Reporting Period					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total

NOTE "16"

(Rs. in Lakhs)

**TRADE RECEIVABLES**

Undisputed Trade Receivables- Considered Goods	997.35	35.79	-	-	-	1033.14
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
<b>Total</b>						<b>1033.14</b>

Particulars	Figures For the Previous Reporting Period					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total

(Rs. in Lakhs)

Undisputed Trade Receivables- Considered Goods	614.84	9.70	-	-	-	624.54
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
<b>Total</b>						<b>624.54</b>



For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

NOTE '17'

(Rs. in Lakhs)

**CASH AND CASH EQUIVALENTS**

**A. BALANCES WITH BANK**

**- Balance with Banks**

-In Current Accounts

5.01

1.73

-In Fixed Deposit Accounts

- As Margin Money with Bank

11.85

7.63

- Other Deposit

16.86

9.36

**- Other Bank Balances**

-In Fixed Deposit with more than 12 months maturity

- As Margin Money with Bank

- Other Deposit

**- Cash on Hand**

39.05

35.14

**TOTAL**

**55.91**

**44.50**

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

NOTE '18'

(Rs. in Lakhs)

**SHORT TERM LOANS AND ADVANCES**

**Others**

Advance for Capital Expenses

Advances to Suppliers

Prepaid Expenses

Advances Staff and Others

Earnest Money Deposit

Balance with Statutory Authorities

15.54

31.18

10.88

11.74

1.30

-0.05

11.03

11.03

319.51

360.07

**TOTAL**

**358.26**

**413.98**

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

NOTE '19'

(Rs. in Lakhs)

**OTHER CURRENT ASSETS**

Other Current Asset

0.69

0.69

0.69

0.69



MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
<b>NOTE '20'</b>		
<b>OTHER INCOME</b>		
Interest	0.98	2.17
Duty Drawback/RODTEP Received	0.66	-
Foreign Exchange Rate Difference	-	-
Other non-operating income (net of expenses)	-	-
Amount Written Off	79.10	18.35
<b>TOTAL</b>	<b>80.74</b>	<b>20.52</b>

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
<b>NOTE '21'</b>		
<b>COST OF MATERIAL CONSUMED</b>		
<b>Raw Material Consumed</b>		
Opening Stock	183.07	127.04
Add: Purchases	1099.75	710.55
	1282.81	837.58
Less: Transfer to other Branch	0.00	18.73
Less : Closing Stock	227.29	183.07
	1055.52	635.79
	1055.52	635.79
<b>Packing Material Consumed</b>		
Opening Stock	186.30	107.59
Add: Purchases	380.32	854.85
Design and Development	-	-
	566.62	962.44
Less : Closing Stock	224.50	186.30
	342.13	776.13
	342.13	776.13
<b>TOTAL COST OF MATERIAL CONSUMED</b>	<b>1397.65</b>	<b>1411.92</b>
Less: Sample Sale	-	-
<b>NET-COST OF MATERIAL CONSUMED</b>	<b>1397.65</b>	<b>1411.92</b>

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
<b>NOTE '22'</b>		
<b>Changes in Inventory of Finished Goods and Work in Process</b>		
<b>Opening Stock</b>		
Work-in Process	66.10	23.70
Finished Goods	36.21	7.25
Stock In Trade	0.50	0.50
	102.81	31.45
<b>Less : Closing Stock</b>		
Work-in-Process	150.59	66.10
Finished Goods	11.52	36.21
Stock In Trade	-	0.50
	162.11	102.81
<b>Stock Decreased /( Increased ) by</b>	<b>-59.29</b>	<b>-71.36</b>

For MEDICAMEN ORGANIS LTD  
  
 Director

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
NOTE '23'		
(Rs. in Lakhs)		
<b>EMPLOYEE BENEFITS EXPENSES</b>		
Salaries & Allowances	250.80	229.17
Contribution to P.F and E.S.I.C.	14.86	13.90
Workmen and Staff Welfare Expenses	17.14	5.31
Directors Remuneration	32.87	38.97
<b>TOTAL</b>	<b>315.66</b>	<b>287.36</b>

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
NOTE '24'		
(Rs. in Lakhs)		
<b>FINANCE COSTS</b>		
<b>Interest Expense</b>		
Interest on Term Loan	3.93	12.31
Interest on Working Capital	46.67	28.44
Interest on Car Loan	2.94	1.36
Interest Others	1.99	0.74
<b>TOTAL</b>	<b>55.54</b>	<b>42.85</b>

For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

Particulars	Figures as at the end of current reporting period ( as at 31.03.2023)	Figures as at the end of previous reporting period ( as at 31.03.2022)
-------------	---	--

NOTE '25'

(Rs. in Lakhs)

**OTHER EXPENSES**

**Manufacturing Expenses**

Labour Charges	87.33	85.31
Clearing and forwarding	-	0.96
Power, Fuel & Water	81.62	71.70
Consumable Stores	5.27	7.82
Freight & Cartage Inwards	26.74	15.94
Analysis & Testing Charges	23.00	18.67
Laboratories Expenses	6.13	6.59
Effluent Treatment Expenses	2.63	2.31
<b>Repair &amp; Maintenance</b>		
-Building	0.26	0.82
-Machines & Electricals	5.21	11.74
-Others	3.17	3.56
<b>TOTAL "A"</b>	<u>241.36</u>	<u>225.41</u>

**Administrative, Selling & Other Expenses**

Legal & Professional Charges	11.23	10.23
Security Services Charges	23.35	21.20
Registration Charges	1.89	2.49
Bank Charges	4.66	3.75
Travelling & Conveyance	5.89	5.58
Fee & Subscription	5.16	3.06
Miscellaneous Expenses	15.57	16.76
Rates & Taxes	0.38	-
House Keeping Expenses	1.41	1.79
Communication Expenses	4.08	3.98
Printing & Stationery	4.40	3.86
Vehicle Running Expenses	4.63	2.51
Distribution Expenses	9.51	2.59
Commission On Sale	24.13	36.84
Computer Expenses	2.20	3.68
Office Expenses	-	-
Business Promotion Expenses	5.60	1.09
Foreign Exchange Fluctuation	1.42	0.09
Insurance		
----- Vehicals	1.59	1.08
----- Stocks & Building	2.66	1.97
----- Others	0.37	0.31
Rent	4.06	3.39
<b>Auditors' Remuneration</b>		
Audit Fees	2.00	2.00
<b>TOTAL "B"</b>	<u>136.17</u>	<u>128.23</u>

**TOTAL "A+B"**

<u>377.54</u>	<u>353.64</u>
---------------	---------------



For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

**NOTE `26`: Details of Export**

Value of Exports Calculated on F.O.B. basis* (Based on shipping Bills)	Rs.3,68,100 (Nil)
---	----------------------

\* Excluding Domestic Sales for Export against LUT

**NOTE `27`:**

The outstanding balances as on March 31, 2023 in respect of parties are subject to Verification.

**NOTE `28`:**

Earnings Per Share (EPS) – The numerator and denominator used to calculate Basic and Diluted Earnings per Share:

Particulars	(In Rupees)	
	31.03.2023	31.03.2022
Net Profit/(Loss) After Tax (Rs.)	1,25,25,859	7,83,171
Equity Shares (Nos.)	60,00,000	60,00,000
Nominal Value of Equity Share (Rs.)	10.00	10.00
Earnings Per Share Basic (Rs.)	2.09	0.13
Earnings Per Share Diluted (Rs.)	2.09	0.13

**NOTE `29`:**

Information required to be disclosed under Micro, Small and Medium Enterprises Development Act, 2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reasons.

**NOTE `30`:**

**Contingent Liabilities:** In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

**NOTE `31`:**

The Company has one segment of activity namely "Pharmaceuticals".

**NOTE `32`:**

In view of the requirements of Schedule II of the Companies Act 2013 ("Act"), depreciation for the year has been provided based on the lives prescribed under the schedule II.



For MEDICAMEN ORGANICS LTD.  
  
 Director  
  
 Director

**NOTE `33`:**

Related party disclosure as required by AS-18: Related Party Disclosures' notified by the Companies (Accounting Standard) Rules, 2006 are given below :

Name and Relationships of the Related Parties:

- (i) **Associate Concern**
  - (a) Red Line Healthcare.
  - (b) Red Line Healthcare Pvt Ltd.
- (ii) **Key Management Personnel**
  - (a) Ms. Ritu Gupta
  - (b) Sri Bal Kishan Gupta
  - (c) Sri Ashutosh Gupta
  - (d) Sri Shailesh Hari Mohan Gaur

(Rs. in Lakhs)

Transactions with Related Parties	Enterprises over which key managerial person can exercise significant influence	Key Management Personnel
<b><u>Loan Received</u></b>		
Redline Healthcare Private Limited	4.82 (9.00)	- (-)
<b><u>Income</u></b>		
Sales of Material/Goods/ Others ➤ Red Line Healthcare	30.08 (24.36)	- (-)
<b><u>Expenditure</u></b>		
Purchase of Material • Red Line Healthcare	116.58 (93.69)	- (-)
Rent	- (-)	- (-)
Remuneration		
1. Bal Kishan Gupta	- (-)	15.35 (13.51)
2. Ritu Gupta	- (-)	6.07 (5.02)
3. Ashutosh Gupta	- (-)	7.02 (7.47)
4. Hukam Chand Sharma	- (-)	- (8.25)
5. Shailesh Harimohan Gaur	- (-)	6.99 (6.98)

For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director

*[Signature]*  
Director

O/S Payables as on 31.03.2023		
• Redline Healthcare Private Limited	13.82 (9.00)	
• Redline Healthcare	108.01 (68.16)	

**NOTE '34':**

The company has not during the year Capitalized which is shown as capital work in progress as on 31<sup>st</sup>, Mar, 2023,

**NOTE '35':**

Previous Year's figures have been regrouped or recast wherever considered necessary.

***Rounding off Amounts***

All amounts disclosed in the financial statements and notes have been rounded off to nearest lakhs as per the requirement of schedule III unless otherwise stated.

As per our report of even date attached

For **ASHOK SHARMA & ASSOCIATES,**

Chartered Accountants

(Aditya Choudhary)

Partner

M. No – 528486

UDIN : 23528486 B9XC RN3705

For **MEDICAMEN ORGANICS LTD.**  
For **MEDICAMEN ORGANICS LTD.**

Director

B. K. Gupta

Director

DIN:00032772

Director

Ashutosh Gupta

Director

DIN:00039995

Place- New Delhi

Date- 07-09-2023



# MEDICAMEN Organics Limited

**Regd. & corporate Office :** 10, Community Center No. 2, Ashok Vihar, Phase-II, Delhi-110052 (India)  
Tel. : 011-27430249 | Tel. Fax : 011-27138171

**Sales Office :** 104, Sawan Park Extn., Ashok Vihar Phase-III, New Delhi-110052 (India)

**E-mail :** chairmen@mediorganics.in | **CIN No. :** U74899DL1995PLC066416 | **GSTIN :** 07AABCM4302P1ZF

## NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the Annual General Meeting of M/s Medicamen Organics Limited will be held on Saturday, the 30<sup>th</sup> day of September 2023, at 10:30 A.M., at the Registered office of the Company situated at 10, Community Centre No. 2, Ashok Vihar Phase-II, Delhi-110052 to transact the following business:

### ORDINARY BUSINESS

1. To receive, consider and adopt the Audited Balance Sheet as at 31<sup>st</sup> March 2023, the statement of Profit & Loss Account and Cash flow Statement for the year ended on that and the Reports of Auditor's and Directors thereon and if thought fit to pass with or without modification(s) the following resolution as Ordinary Resolution:

**"RESOLVED THAT** the Audited Financial Statements of the Company for the Financial Year ended 31<sup>st</sup> March 2023 and the Reports of the Board of Directors and Statutory Auditors thereon laid before this Meeting, be and are hereby received, considered and adopted."

2. To appoint a Director in place of Shri Bal Kishan Gupta (DIN: 00032772), who retires by rotation and is eligible, offers himself for reappointment and if thought fit to pass with or without modification(s) the following resolution as Ordinary Resolution:

**"RESOLVED THAT** pursuant to the provisions of Section 152 of the Companies Act, 2013 and relevant rules framed thereunder, including any modification(s) thereto or re-enactment(s) thereof, for the time being in force, Mr. Bal Kishan Gupta (DIN: 00032772), who retires by rotation at this meeting and being eligible offers himself for re-appointment, be and is hereby re-appointed as a Whole Time Director of the Company, liable to retire by rotation."

### SPECIAL BUSINESS

3. To ratify the term of Mr. Bal Kishan Gupta as Whole-Time Director after attaining the age of 70 years and if deemed fit, pass with or without modification(s) the following resolution as a Special Resolution:

**"RESOLVED THAT** based on the recommendation of the Board of Directors, pursuant to the provisions of Sections 196, 196(3), 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and Schedule V thereto and the Rules made thereunder including any amendment(s), statutory modification(s) or re-enactment(s) thereof for the time being in force and the Articles of Association of the company and subject to such other approvals as may be necessary, the consent of the Company be and is hereby accorded to ratify the term of Mr. Bal Kishan Gupta (DIN: 00032772) as Whole-time Director of the Company who has attained the age of 70 years for a term up to 30<sup>th</sup> April 2026. The remuneration payable to him, including the increase in remuneration and/or waiver of refund of excess remuneration and/or the remuneration to be paid in case of inadequate profits or no profits in any financial year during the tenure of appointment as set out below:

**For MEDICAMEN ORGANICS LTD.**

*Bal Kishan Gupta*

Director

**For MEDICAMEN ORGANICS LTD.**

*Bal Kishan Gupta*

Director

Works :

Unit 1 : Plot No. 60, Sector-6A, I.I.E. SIDCUL, Ranipur, Haridwar - 249 403 (U.K.) **GSTIN :** 05AABCM4302P1ZJ

Unit 2 : Plot No. 61, Sector-6A, I.I.E. SIDCUL, Ranipur, Haridwar - 249 403 (U.K.) **GSTIN :** 05AABCM4302P3ZH

(A) Salary: Rs. 99,314/- (Rupees Ninety-Nine Thousand Three Hundred Fourteen only) for the month of April and Rs. 99,914/- (Rupees Ninety-Nine Thousand Nine Hundred Fourteen only) from May to September.

(B) Perquisites: In addition to remuneration mentioned at (A) above, he shall also be eligible for the following perquisites which shall not be included in the computation of the ceiling as specified in Para (A) above:

- (i) Contribution to Provident Fund as per the Rules of the Company.
- (ii) Suitable insurance cover for self under Group Term Insurance and Mediclaim Policy.
- (iii) He shall be entitled to the company's cars as per the prevailing policy of the Company.

In addition, he shall be eligible for club facilities, reimbursement of actual entertainment, traveling, boarding and lodging expenses incurred by him in connection with the Company's business and such other benefits/amenities and other privileges, as may be available from time to time to any other senior executives of the Company.

**RESOLVED FURTHER THAT** where in any financial year during the tenure of the said Whole-time Director, the Company has no profits or its profits are inadequate, the remuneration as may be approved by the Board of Directors of the Company from time to time shall be paid as minimum remuneration.

**RESOLVED FURTHER THAT** any Director of the Company be and is hereby authorized to do all such acts, deeds and things or to execute any document and writings as may be required in order to give effect to this resolution or as otherwise considered by the Board to be in the best interest of the Company, as it may deem fit."

4. To revise the terms of appointment of Mr. Ashutosh Gupta (DIN: 00039995), Director of the Company, and if thought fit to pass with or without modification(s) the following resolution as Ordinary Resolution:

**"RESOLVED THAT** pursuant to the approval of the Board of Directors of the Company and in accordance with the provisions of Sections 196, 197, 198 and 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), approval of the Members of the Company be and is hereby accorded to revise the terms and conditions of the original appointment of Mr. Ashutosh Gupta (DIN: 00039995), from Whole Time Director with effect from 1<sup>st</sup> April 2023 to 30<sup>th</sup> April 2025. The remuneration payable to him, including the increase in remuneration and/or waiver of refund of excess remuneration and/or the remuneration to be paid in case of inadequate profits or no profits in any financial year during the tenure of appointment as set out below:


(A) Salary: Rs. 58,518/- (Rupees Fifty Eight Thousand Five Hundred Eighteen only) per month.

(B) Perquisites: In addition to remuneration mentioned at (A) above, he shall also be eligible for the following perquisites which shall not be included in the computation of the ceiling as specified in Para (A) above:


- (i) Contribution to Provident Fund as per the Rules of the Company.
- (ii) Suitable insurance cover for self under Group Term Insurance and Mediclaim Policy.
- (iii) He shall be entitled to the company's cars as per the prevailing policy of the Company.

In addition, he shall be eligible for club facilities, reimbursement of actual entertainment, traveling, boarding and lodging expenses incurred by him in connection with the Company's business and such other benefits/amenities and other privileges, as may be available from time to time to any other senior executives of the Company.

For MEDICAMEN ORGANICS LTD.

  
Director

For MEDICAMEN ORGANICS LTD.

  
Director

**RESOLVED FURTHER THAT** where in any financial year during the tenure of the said Whole-time Director, the Company has no profits or its profits are inadequate, the remuneration as may be approved by the Board of Directors of the Company from time to time shall be paid as minimum remuneration.

**RESOLVED FURTHER THAT** any Director of the Company be and is hereby authorized to do all such acts, deeds and things or to execute any document and writings as may be required in order to give effect to this resolution or as otherwise considered by the Board to be in the best interest of the Company, as it may deem fit.”


**Place: New Delhi**

**Date: 07, September 2023**

For and on behalf of Board of Directors

**Medicamen Organics Limited**

**For MEDICAMEN ORGANICS LTD.**



**Bal Kishan Gupta**  
Director

DIN: 00032772


B-4, Satyawati Colony,  
Ashok Vihar Phase-III, Delhi-52

**Notes :**

1. An Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 in respect of Items No. 1 to 4 set out in the Notice is annexed hereto
2. A member entitled to attend and vote is entitled to appoint a proxy to attend and vote instead of himself/ herself and the proxy need not be a member of the Company. The instrument of proxy in order to be effective, must be deposited at the Registered Office of the Company, duly completed and signed, not less than 48 hours before the meeting. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
3. Corporate Members intending to send their authorized representatives to attend the meeting are requested to send to the Company a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the Meeting.
4. Members are requested to notify immediately any change of address to the Company in respect of the shares held in physical form together with a proof of address viz. Electricity Bill, Telephone Bill, Ration Card, Voter ID Card, Passport etc.
5. All documents referred to in the accompanying notice and explanatory statements are open for inspection at the registered office of the Company on all working days during business hours.
6. The voting rights of members shall be in proportion to their shares of the paid-up equity share capital of the Company.
7. Members holding shares in the physical form are requested to apply for dematerialization of the shares.

For and on behalf of Board of Directors  
**Medicamen Organics Limited**

**For MEDICAMEN ORGANICS LTD.**

  
**Bal Kishan Gupta**  
Director

DIN: 00032772

B-4, Satyawati Colony,  
Ashok Vihar Phase-III, Delhi-52

**Place : New Delhi**

**Date : 07 September 2022**

**EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013**

As required under section 102 of the Companies Act, 2013, the following Explanatory Statements set out all material facts relating to the business mentioned under Item No. 3 and 4 accompanying Notice of Annual General Meeting dated 30<sup>th</sup> September 2023:

**Item No. 3:**

To continue the appointment of Mr. Bal Kishan Gupta (DIN: 00032772) as Whole Time Director, after attaining the age of 70 years and pursuant to Section 196(3)(a) of the Companies Act, 2013, "No company shall appoint or continue the employment of any person as managing director, whole-time director or manager who is below the age of twenty-one years or has attained the age of seventy years:

Provided that appointment of a person who has attained the age of seventy years may be made by passing a special resolution in which case the explanatory statement annexed to the notice for such motion shall indicate the justification for appointing such person;"

The Board considers the continuation of Mr. Bal Kishan Gupta on the terms and conditions to be beneficial to the interests of the Company, considering his long experience and the services being rendered by him and commends the Special Resolution set out at Item No. 3 of the Notice for approval by the Members.

None of the Directors, Key Managerial Personnel, and /or their relatives, except Mr. Bal Kishan Gupta is, in any way, concerned or interested in the said resolution.

**Item No. 4:**


To change the terms and conditions of the appointment of Mr. Ashutosh Gupta (DIN: 00039995), Director of the Company by the revision in the remuneration payable to him and duly approved by the Board of Directors in their meeting held on September 07, 2023, subject to the approval of shareholders in the ensuing Annual General Meeting.

Further, in terms of the provisions of Section 197 and Part II of Schedule V of the Companies Act, 2013, a Company may pay the remuneration to its Whole Time Director as per the table defined under Part II of the aforesaid schedule being the "other director".

None of the Directors, Key Managerial Personnel, and /or their relatives, except Mr. Ashutosh Gupta is, in any way, concerned or interested in the said resolution.

For and on behalf of the Board of Directors  
**Medicamen Organics Limited**

**For MEDICAMEN ORGANICS LTD.**

  
**Bal Kishan Gupta**  
Director

DIN: 00032772

B-4, Satyawati Colony,  
Ashok Vihar Phase-III, Delhi-52

Place: New Delhi

Date: 07, September 2023

**ATTENDANCE SLIP**

**(Please complete this attendance slip and hand it over at the entrance of the venue)**

I hereby record my presence at the Annual General Meeting of the Members of the Medicamen Organics Limited will be held at the Registered office of the Company on Saturday, **30<sup>th</sup> day of September 2023, at 10:30 A.M, at the Registered office of the Company situated at 10, Community Centre No. 2, Ashok Vihar Phase-II, Delhi-110052.**

Folio No. /DP ID- Client ID: .....  
Full Name of the Shareholder in Block Letters: .....  
No. of Shares held: .....

Name of Proxy (if any) in Block Letters:

.....

**For MEDICAMEN ORGANICS LTD.**

*Signature*  
**Director**

Signature of the Shareholder/Proxy/Representative\*

**For MEDICAMEN ORGANICS LTD.**

*Signature*  
**Director**

\*Strike out whichever is not applicable.

FORM NO. MGT- 11

Proxy Form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

I/We, being the member(s) of the ..... Shares of the above named company, hereby appoint

1. Name: .....  
Address: .....  
Email Id: .....  
Signature: ..... or failing him
2. Name: .....  
Address: .....  
Email Id: .....  
Signature: ..... or failing him
3. Name: .....  
Address: .....  
Email Id: .....

Signature: ..... or failing him as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 25<sup>th</sup> Annual general Meeting of the company, to be held on the Thursday 31<sup>st</sup> December, 2020 at 10.30 am at 10, Community Centre No. 2, Ashok Vihar Phase-II, Delhi-110052 and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.

1. ....
2. ....
3. ....

Signed this ..... day of ..... 2020

**For MEDICAMEN ORGANICS LTD.**

Signature of shareholder .....

Director

Signature of Proxy holder(s) .....

**For MEDICAMEN ORGANICS LTD.**  
*[Signature]*  
Director

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered office of the Company, not less than 48 hours before the commencement of the Meeting.

Name of the member(s):

Registered address:


E-mail Id:

Folio No/Client Id:

DP ID:

## ROUTE MAP OF THE COMPANY


REVENUE  
STAMP



## ROUTE MAP

Route Map to the venue of AGM of Medicamen Organics Limited

Venue of AGM: 10, Community Centre No. 2, Ashok Vihar Phase-II, Delhi-110052



9 min (3.0 km) via Chaudhary Gulab Singh Marg/Satyawathi  
College Rd and महाराजा नाहर सिंह मार्ग

For MEDICAMEN ORGANICS LTD.

*Sushil*  
Director

For MEDICAMEN ORGANICS LTD.

*Shantanu*  
Director



# MEDICAMEN Organics Limited

Regd. & corporate Office : 10, Community Center No. 2, Ashok Vihar, Phase-II, Delhi-110052 (India)

Tel. : 011-27430249 | Tel. Fax : 011-27138171

Sales Office : 104, Sawan Park Extn., Ashok Vihar Phase-III, New Delhi-110052 (India)

E-mail : chairmen@mediorganics.in | CIN No. : U74899DL1995PLC066416 | GSTIN : 07AABCM4302P1ZF

## DIRECTORS' REPORT

To the Members of  
Medicamen Organics Limited

The Board of Directors of your Company is pleased to present their report on the working of the Company for the year ended 31<sup>st</sup> March, 2023 together with the Audited Accounts of the Company.

### 1. FINANCIAL PERFORMANCE SUMMARY

The Company's financial performance, for the period ended 31<sup>st</sup> March 2023 is summarized below:

(In Rupees)

Particulars	FY 2022-23	FY 2021-22
Total Revenue	22,95,45,224	21,18,04,081
Total Expenses	21,67,10,549	21,05,14,015
Profit/(Loss) before Tax	1,28,34,675	12,90,066
Current Tax	1,00,000	1,00,000
Deferred Tax	2,08,816	4,06,895
Profit/(Loss) after tax	1,25,25,859	7,83,171

### 2. DIVIDEND

The Directors have not recommended payment of any dividend during the period under review.

### 3. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirement under Section 134(3)(c) of the Companies Act, 2013 with respect to the Directors' Responsibility Statement, the Board of Directors of the Company hereby states and confirms that:

- in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for the year under review;
- the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- the directors have prepared the annual accounts on a going concern basis.

For MEDICAMEN ORGANICS LTD.

Director

For MEDICAMEN ORGANICS LTD.

Director

#### Works :

Unit 1 : Plot No. 60, Sector-6A, I.I.E. SIDCUL, Ranipur, Haridwar - 249 403 (U.K.) GSTIN : 05AABCM4302P1ZJ

Unit 2 : Plot No. 61, Sector-6A, I.I.E. SIDCUL, Ranipur, Haridwar - 249 403 (U.K.) GSTIN : 05AABCM4302P3ZH

- e) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

#### 4. SECRETARIAL STANDARDS

The Directors state that applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively, have been duly followed by the Company.

#### 5. DIRECTORS AND KEY MANAGERIAL PERSONNEL AND CHANGES AMONG THEM

There has been no change in the constitution of Board during the period under review.

#### 6. STATE OF AFFAIRS

There has been no change in the nature of business of the Company during the financial year ended 31<sup>st</sup> March 2023. The Revenue from operations for the period ended then stood at Rs. 22,14,71,499

#### 7. NUMBER OF MEETINGS OF BOARD OF DIRECTORS

During the financial year under review, 4 (Four) meetings of the Board of Directors of the Company were held as under:


Sr. No.	Date of Meeting	Directors present in the Board Meeting
1	12/05/2022	3
2	15/06/2022	3
3	29/07/2022	3
4	03/09/2022	3
5	26/12/2022	3
6	27/03/2023	3

The maximum interval between any two Board Meetings did not exceed 120 (One hundred and twenty) days. The details of attendance of each Director at Board Meetings are as follows:

S. No	Name of the Director	Board Meetings	
		No. of Meetings held	No. of Meetings attended
1.	BAL KISHAN GUPTA	6	6
2.	ASHUTOSH GUPTA	6	6
3.	SHAILESH HARIMOHAN GAUR	6	6

#### 8. CHANGE IN NATURE OF BUSINESS

There were no significant changes in the nature of the business of the Company during the period under review.

For MEDICAMEN ORGANICS LTD.  
  
Director

For MEDICAMEN ORGANICS LTD.  
  
Director

## **9. AUDIT**

M/s Ashok Sharma & Associates, Chartered Accountants having Firm Registration No. 004161N, who will be the ongoing statutory Auditors of the Company till the conclusion of the Annual General Meeting of the Company to be held in the year 2024.

M/s Ashok Sharma & Associates, Chartered Accountants have also given their confirmation regarding the compliance of conditions prescribed under Sections 139 and 141 of the Act in regard to continuation of their term.

The report of the Statutory Auditors along with notes to Schedules is enclosed to this Report. The explanation to the observations made in the Auditors' Report has been submitted by the Board.

### **Explanation to the qualification in Auditors' Report**

The Auditors has not specified any qualification in their report for the period ending 31<sup>st</sup> March, 2023. Hence, no explanation is required by the Directors.

## **10. MAINTENANCE OF COST RECORDS**

The Directors state that the overall turnover of the company does not exceed the limit prescribed for maintenance of Cost Records as specified by the Central Government under Section 148(1) of the Companies Act, 2013, accordingly such accounts and records are not made and maintained by the Company.

## **11. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS**

The particulars of loans, guarantees or investments made during the Financial Year 2022-23, if any, have been disclosed in the notes attached to and forming part of the Financial Statements of the Company prepared for the Financial Year ended March 31, 2023, as per the provisions of Section 186 and Section 134(3) (g) of the Companies Act, 2013.

## **12. RELATED PARTY TRANSACTIONS**

The Company has entered into transactions with related parties in accordance with section 188 of the Companies Act 2013 and the rules made thereunder. The transactions were in the ordinary course of business and on an arm's length basis. None of the transactions entered by the company were in conflict with the interest of company & detailed Disclosures in respect of such transactions has been made in the notes to accounts forming part of the auditor's report.

## **13. TRANSFER TO RESERVES**

For the period ended 31<sup>st</sup> March 2023, the Company has not transferred any sum to Reserve.

## **14. TRANSFER OF UNCLAIMED/UNPAID AMOUNT TO INVESTOR EDUCATION AND PROTECTION FUND**

Pursuant to provisions of the Act read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended, ('Rules'), the dividend which remains unclaimed or unpaid for a period of seven years from the date of transfer to the Unpaid Dividend Account

For MEDICAMEN ORGANICS LTD.

  
Director

For MEDICAMEN ORGANICS LTD.

  
Director

of the Company and shares on which dividend are unclaimed or unpaid for a consecutive period of seven years or more are liable to be transferred to IEPF. This clause is not applicable.

**15. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY**

There were no material changes and commitments affecting the financial position of the Company between the end of period to which these financial statements relate and the date of this Report.

**16. DEPOSIT FROM PUBLIC**

The Company has not accepted any deposits from public and as such, no amount on account of principal or interest on deposits from public was outstanding as on the date of the balance sheet.

**17. DETAILS OF MONEY ACCEPTED FROM DIRECTOR**

During the period under review, the Company has accepted money in the form of an unsecured loan from the director or relative of the director of the Company amounting to Rs. 5,92,90,608.35.

**18. INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS**

The Board has adopted the procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting record, and the timely preparation of reliable financial disclosures.

**19. ISSUE OF EQUITY SHARES WITH DIFFERENTIAL RIGHTS, SWEAT EQUITY, ESOS, ETC., IF ANY**

The Company has not issued shares with differential voting rights nor granted stock options nor sweat equity during the period under review.

**20. RISK MANAGEMENT POLICY**

The Board of Directors facilitates the execution of Risk Management Practices in the Company, in the areas of risk identification, assessment, monitoring, mitigation and reporting. At present, the Company has not identified any element of risk which may threaten the existence of the Company.


**21. SUBSIDIARIES/ ASSOCIATES OR JOINT VENTURES**

During the period under review, no Company has become or ceased to be Subsidiary, Associates or Joint Venture of the Company.


**23. SIGNIFICANT ORDERS PASSED BY REGULATORS OR COURTS OR TRIBUNAL**

There are no significant material orders passed by the Regulators / Courts /Tribunals which would impact the going concern status of the Company and its future operations.

For MEDICAMEN ORGANICS LTD.

  
Director

For MEDICAMEN ORGANICS LTD.

  
Director

**24. DETAILS OF ESTABLISHMENT OF VIGIL MECHANISM, IF ANY,**

The threshold limit provided under Section 177(9) read with Rule 7 of the Companies (Meeting of Board and its Power) Rule, 2014 is not applicable on the Company.

**25. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO**

The particulars as required under the provisions of Section 134(3) (m) of the Companies Act, 2013 in respect of conservation of energy and technology absorption have not been furnished considering the nature of activities undertaken by the company during the year under review.

**26. DISCLOSURE IN TERMS OF VARIOUS PROVISIONS OF THE COMPANIES ACT, 2013**

The status of the Company being a Limited Company and not having material profit/turnover/Bank's borrowings, the provision related to

- (a) Statement on declaration given by Independent Directors (Section 149)
- (b) Formation of Audit Committee (Section 177)
- (c) Formation of Nomination and Remuneration Committee (Section 178)
- (d) Undertaking formal Annual Evaluation of Board and that of its committees and the individual Directors
- (e) Undertaking Secretarial Audit (Section 204) are not applicable to the Company and hence no comment is invited in this regard.

**27. SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013**

The company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Further, during the year, no complaint regarding Sexual Harassment of Women at workplace has been received by the company.

**28. ESTABLISHMENT OF CSR POLICY AND RELATED DISCLOSURE / COMPLIANCES**

The Provisions of Section 135 of the Companies Act, 2013 are not applicable to the Company as it does not fulfil any of the conditions specified in Section 135(1) of the Companies Act, 2013


**29. FRAUDS REPORTED BY AUDITORS UNDER SECTION 143(12), OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT.**

The Statutory Auditors have not reported any incident of fraud to the Board of Directors of the Company.


**30. DETAILS OF APPLICATION / ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016**

Neither any application was made nor any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the financial year.

For MEDICAMEN ORGANICS LTD.

  
Director

For MEDICAMEN ORGANICS LTD.

  
Director


**31. DETAILS OF THE DIFFERENCE BETWEEN THE AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE-TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING A LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF**

As the Company has not done any one-time settlement during the year under review hence no disclosure is required.

**32. ACKNOWLEDGEMENT**

We take the opportunity to express our deep sense of gratitude to Bankers and customers for their continued guidance and support. Your directors would like to record their sincere appreciation of their dedicated efforts put in by employees across all levels in the organization, which have enabled the company to start operations. And to you, our shareholders, we are deeply grateful for the confidence and faith that you have always placed on us.

For and on Behalf of  
Medicamen Organics Limited  
For **MEDICAMEN ORGANICS LTD.**

  
Bal Kishan Gupta  
Director  
DIN: - 00032772

For **MEDICAMEN ORGANICS LTD.**  
  
Director

Ashutosh Gupta  
Director  
DIN: - 00039995

Date: 07/09/2023  
Place: Delhi